JP2001518496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001518496A5 JP2001518496A5 JP2000514630A JP2000514630A JP2001518496A5 JP 2001518496 A5 JP2001518496 A5 JP 2001518496A5 JP 2000514630 A JP2000514630 A JP 2000514630A JP 2000514630 A JP2000514630 A JP 2000514630A JP 2001518496 A5 JP2001518496 A5 JP 2001518496A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- membered
- independently selected
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 22
- 125000001072 heteroaryl group Chemical group 0.000 description 21
- 125000001424 substituent group Chemical group 0.000 description 18
- 229910052736 halogen Inorganic materials 0.000 description 17
- 150000002367 halogens Chemical group 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 239000001257 hydrogen Substances 0.000 description 16
- 125000004953 trihalomethyl group Chemical group 0.000 description 15
- 150000002148 esters Chemical group 0.000 description 14
- 102100030011 Endoribonuclease Human genes 0.000 description 12
- 101710199605 Endoribonuclease Proteins 0.000 description 12
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 12
- 150000007942 carboxylates Chemical group 0.000 description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000376 reactant Substances 0.000 description 8
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- -1 -COOH carboxylic acid Chemical class 0.000 description 2
- BVQVLAIMHVDZEL-UHFFFAOYSA-N 1-phenyl-1,2-propanedione Chemical compound CC(=O)C(=O)C1=CC=CC=C1 BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229920001577 copolymer Chemical class 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- MTMONFVFAYLRSG-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-2-oxoacetaldehyde Chemical compound OC1=CC=C(C(=O)C=O)C=C1 MTMONFVFAYLRSG-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical group NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 description 1
- 0 C*C1=Nc2nc(**)c(*)c(*)c2N(C)CC1* Chemical compound C*C1=Nc2nc(**)c(*)c(*)c2N(C)CC1* 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical group [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- LJDZFAPLPVPTBD-UHFFFAOYSA-N nitroformic acid Chemical group OC(=O)[N+]([O-])=O LJDZFAPLPVPTBD-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6112397P | 1997-10-06 | 1997-10-06 | |
| US60/061,123 | 1997-10-06 | ||
| PCT/US1998/020910 WO1999017759A2 (en) | 1997-10-06 | 1998-10-05 | Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001518496A JP2001518496A (ja) | 2001-10-16 |
| JP2001518496A5 true JP2001518496A5 (https=) | 2006-01-05 |
Family
ID=22033733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000514630A Withdrawn JP2001518496A (ja) | 1997-10-06 | 1998-10-05 | ５−アザキノキサリンをベースとする化合物によりセリン／トレオニンプロテインキナーゼの機能を調整する方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6180631B1 (https=) |
| EP (1) | EP1028729B1 (https=) |
| JP (1) | JP2001518496A (https=) |
| KR (1) | KR100633270B1 (https=) |
| CN (1) | CN1169527C (https=) |
| AR (1) | AR013542A1 (https=) |
| AT (1) | ATE336250T1 (https=) |
| AU (1) | AU757585B2 (https=) |
| BG (1) | BG64969B1 (https=) |
| BR (1) | BR9814814A (https=) |
| CA (1) | CA2306257C (https=) |
| CY (1) | CY1106223T1 (https=) |
| CZ (1) | CZ298775B6 (https=) |
| DE (1) | DE69835612T2 (https=) |
| DK (1) | DK1028729T3 (https=) |
| ES (1) | ES2268791T3 (https=) |
| HU (1) | HUP0100302A3 (https=) |
| IL (2) | IL135103A0 (https=) |
| MX (1) | MXPA03011007A (https=) |
| NO (1) | NO316598B1 (https=) |
| NZ (1) | NZ503431A (https=) |
| PL (1) | PL192039B1 (https=) |
| PT (1) | PT1028729E (https=) |
| RU (1) | RU2223753C2 (https=) |
| SK (1) | SK4722000A3 (https=) |
| TR (2) | TR200000906T2 (https=) |
| TW (1) | TWI245765B (https=) |
| UA (1) | UA71555C2 (https=) |
| WO (1) | WO1999017759A2 (https=) |
| ZA (1) | ZA988961B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| EP1158985B1 (en) * | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU1053501A (en) * | 1999-11-02 | 2001-05-14 | Ajinomoto Co., Inc. | Polyazanaphthalene compound and medicinal use thereof |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US20040131504A1 (en) * | 2002-09-17 | 2004-07-08 | Landers James P. | Remote temperature sensing of small volume and related apparatus thereof |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| EP1636585B2 (en) * | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| DE102004022383A1 (de) * | 2004-05-06 | 2005-12-01 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen |
| PT1636228E (pt) * | 2003-05-23 | 2009-02-02 | Aeterna Zentaris Gmbh | Novas piridopirazinas e sua utilização como moduladores de cinases |
| DE10323345A1 (de) * | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| ATE454152T1 (de) * | 2003-06-13 | 2010-01-15 | Novartis Pharma Gmbh | 2-aminopyrimidin-derivate als raf-kinase-hemmer |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| WO2007054556A1 (de) | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
| WO2010003308A1 (zh) * | 2008-07-10 | 2010-01-14 | 卞化石 | 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用 |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| EP2508184A1 (en) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazine derivatives and their use |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| WO2014109414A1 (ja) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| HRP20210319T1 (hr) | 2014-03-26 | 2021-04-30 | Astex Therapeutics Ltd. | Kombinacije inhibitora fgfr i inhibitora igf1r |
| RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
| JP6759514B2 (ja) | 2014-08-01 | 2020-09-23 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | ブロモドメインに対して活性な化合物 |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| US11155555B2 (en) | 2015-09-23 | 2021-10-26 | Janssen Pharmaceutica Nv | Compounds |
| US12012394B2 (en) * | 2018-02-19 | 2024-06-18 | Washington University | Alpha-synuclein ligands |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001017A (en) * | 1972-12-05 | 1977-01-04 | Ciba-Geigy Ag | Process for the photopolymerization of ethylenically unsaturated compounds |
| US4043819A (en) * | 1974-06-11 | 1977-08-23 | Ciba-Geigy Ag | Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE3804990A1 (de) * | 1988-02-18 | 1989-08-31 | Basf Ag | Herbizid wirksame, heterocyclisch substituierte sulfonamide |
| FR2656606B1 (fr) * | 1989-12-28 | 1993-06-25 | Roussel Uclaf | Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure. |
| WO1991015495A1 (en) | 1990-04-02 | 1991-10-17 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| FI935279L (fi) | 1991-05-29 | 1993-11-26 | Pfizer | Tricykliska polyhydroxyltyrosinkinasininhibitorer |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| WO1994003427A1 (en) | 1992-08-06 | 1994-02-17 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5723462A (en) * | 1996-04-26 | 1998-03-03 | Neurogen Corporation | Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| GB9726851D0 (en) * | 1997-12-19 | 1998-02-18 | Zeneca Ltd | Human signal transduction serine/threonine kinase |
-
1998
- 1998-05-10 UA UA2000052578A patent/UA71555C2/uk unknown
- 1998-10-01 ZA ZA9808961A patent/ZA988961B/xx unknown
- 1998-10-05 HU HU0100302A patent/HUP0100302A3/hu not_active Application Discontinuation
- 1998-10-05 AU AU95141/98A patent/AU757585B2/en not_active Ceased
- 1998-10-05 KR KR1020007003656A patent/KR100633270B1/ko not_active Expired - Fee Related
- 1998-10-05 CA CA002306257A patent/CA2306257C/en not_active Expired - Fee Related
- 1998-10-05 ES ES98948606T patent/ES2268791T3/es not_active Expired - Lifetime
- 1998-10-05 MX MXPA03011007A patent/MXPA03011007A/es not_active IP Right Cessation
- 1998-10-05 JP JP2000514630A patent/JP2001518496A/ja not_active Withdrawn
- 1998-10-05 WO PCT/US1998/020910 patent/WO1999017759A2/en not_active Ceased
- 1998-10-05 US US09/166,723 patent/US6180631B1/en not_active Expired - Fee Related
- 1998-10-05 RU RU2000111434/15A patent/RU2223753C2/ru not_active IP Right Cessation
- 1998-10-05 EP EP98948606A patent/EP1028729B1/en not_active Expired - Lifetime
- 1998-10-05 IL IL13510398A patent/IL135103A0/xx not_active IP Right Cessation
- 1998-10-05 TR TR2000/00906T patent/TR200000906T2/xx unknown
- 1998-10-05 NZ NZ503431A patent/NZ503431A/en unknown
- 1998-10-05 AT AT98948606T patent/ATE336250T1/de not_active IP Right Cessation
- 1998-10-05 SK SK472-2000A patent/SK4722000A3/sk unknown
- 1998-10-05 TR TR2001/00385T patent/TR200100385T2/xx unknown
- 1998-10-05 DE DE69835612T patent/DE69835612T2/de not_active Expired - Fee Related
- 1998-10-05 BR BR9814814-1A patent/BR9814814A/pt not_active Application Discontinuation
- 1998-10-05 DK DK98948606T patent/DK1028729T3/da active
- 1998-10-05 CN CNB988099403A patent/CN1169527C/zh not_active Expired - Fee Related
- 1998-10-05 PL PL339860A patent/PL192039B1/pl not_active IP Right Cessation
- 1998-10-05 PT PT98948606T patent/PT1028729E/pt unknown
- 1998-10-05 CZ CZ20001129A patent/CZ298775B6/cs not_active IP Right Cessation
- 1998-10-06 AR ARP980104970A patent/AR013542A1/es unknown
- 1998-10-06 TW TW087116559A patent/TWI245765B/zh not_active IP Right Cessation
-
2000
- 2000-03-15 IL IL135103A patent/IL135103A/en unknown
- 2000-04-05 NO NO20001748A patent/NO316598B1/no unknown
- 2000-04-28 BG BG104392A patent/BG64969B1/bg unknown
- 2000-10-16 US US09/688,199 patent/US6727252B1/en not_active Expired - Fee Related
-
2006
- 2006-10-30 CY CY20061101554T patent/CY1106223T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001518496A5 (https=) | ||
| Basarab et al. | Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: benzisoxazole fusion with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914) | |
| RU2223753C2 (ru) | Способы модулирования функции серин/треонин протеинкиназы соединениями на основе 5-азахиноксалина, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологического состояния организма, фармацевтическая композиция, соединение на основе 5-азахиноксалина и способ его синтеза | |
| RU2000111434A (ru) | Способы модулирования функции серин/треонин протеинкиназы соединениями на основе 5-азахиноксалина, способ идентификации соединений, модулирующих функцию серин/треонин протеинкиназы, способ профилактики или лечения патологического состояния организма, фармацевтическая композиция, соединение на основе 5-азахиноксалина и способ его синтеза | |
| CN1043531C (zh) | 嘧啶衍生物及其制备方法和用途 | |
| NZ513456A (en) | Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders | |
| JP2003506347A5 (https=) | ||
| DK200101216A (da) | Fremgangsmåde til fremstilling af citalopram | |
| Nicolaou et al. | Phosphate prodrugs for amines utilizing a fast intramolecular hydroxy amide lactonization | |
| Papaioannou et al. | Enantioselective synthesis of a mitosane core assisted by diversity-based catalyst discovery | |
| Chen et al. | Variation in biosynthesis and metal-binding properties of isonitrile-containing peptides produced by Mycobacteria versus Streptomyces | |
| Wang et al. | Highly Enantioselective Synthesis of α‐Stereogenic Esters through Catalytic Asymmetric Michael Addition of 4‐Oxo‐4‐arylbutenoates | |
| Einhorn et al. | Alternate Self-Regeneration of Stereocenters: Enantioselective Generation of a C 2-Symmetric Chiral Nitroxide and Its Reduction to the Corresponding, Highly Sterically Hindered Amine | |
| RU2004107847A (ru) | Изоксазолпиридиноны и их применение в лечении болезни паркинсона | |
| Paleo et al. | Enantiospecific Synthesis of N-(9-Phenylfluoren-9-yl)-α-amino Ketones | |
| RU2214404C2 (ru) | Тиазольные производные, способ получения и фармацевтическая композиция на их основе | |
| Lüning et al. | Concave Reagents. 20. Sterically Shielded m-Terphenyls as Selective Agents in General Protonations1 | |
| EP0328125A3 (en) | Process for the enzymatic separation of the optical isomers of racemic alpha-alkyl-substituted primary alcohols | |
| Romero et al. | Inhibitors of Phenylethanolamine N-Methyltransferase That Are Predicted To Penetrate the Blood− Brain Barrier: Design, Synthesis, and Evaluation of 3-Fluoromethyl-7-(N-substituted aminosulfonyl)-1, 2, 3, 4-tetrahydroisoquinolines That Possess Low Affinity toward the α2-Adrenoceptor | |
| Taran et al. | Antibody-catalyzed decarboxylative oxidation of vanillylmandelic acid | |
| EP0330217A3 (en) | Process for the continuous biotechnological preparation of optical isomer s(+) of 2-(6-methoxy-2-naphthyl)propionic acid | |
| CN1427721A (zh) | 肽脱甲酰基酶抑制剂 | |
| JP2004527530A5 (https=) | ||
| KR910000652A (ko) | (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도 | |
| SU1540804A1 (ru) | Способ отбора биологически активных веществ, взаимодействующих с @ - адренорецепторами |